Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson-Gilford progeria syndrome mutation.
about
Molecular ageing in progeroid syndromes: Hutchinson-Gilford progeria syndrome as a modelProgeria: a rare genetic premature ageing disorderTargeting protein prenylation in progeriaWhen lamins go bad: nuclear structure and diseaseRecent advances in understanding the role of lamins in health and diseaseLaminopathies and the long strange trip from basic cell biology to therapyThe defective nuclear lamina in Hutchinson-gilford progeria syndrome disrupts the nucleocytoplasmic Ran gradient and inhibits nuclear localization of Ubc9.Farnesylation of lamin B1 is important for retention of nuclear chromatin during neuronal migration.Assessing the efficacy of protein farnesyltransferase inhibitors in mouse models of progeria.Dynamics of lamin-A processing following precursor accumulation.Genetic studies on the functional relevance of the protein prenyltransferases in skin keratinocytes.The posttranslational processing of prelamin A and disease.Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome.An accumulation of non-farnesylated prelamin A causes cardiomyopathy but not progeria.Progeria syndromes and ageing: what is the connection?Inner nuclear membrane proteins: impact on human disease.Absence of progeria-like disease phenotypes in knock-in mice expressing a non-farnesylated version of progerin.Investigating the purpose of prelamin A processingSulforaphane enhances progerin clearance in Hutchinson-Gilford progeria fibroblasts.Understanding the roles of nuclear A- and B-type lamins in brain development.Modulation of LMNA splicing as a strategy to treat prelamin A diseases.Progerin elicits disease phenotypes of progeria in mice whether or not it is farnesylated.Inhibition of extracellular signal-regulated kinase signaling to prevent cardiomyopathy caused by mutation in the gene encoding A-type lamins.Epidermal expression of the truncated prelamin A causing Hutchinson-Gilford progeria syndrome: effects on keratinocytes, hair and skinAccelerated ageing: from mechanism to therapy through animal models.Increasing the length of progerin's isoprenyl anchor does not worsen bone disease or survival in mice with Hutchinson-Gilford progeria syndrome.Progeroid syndrome patients with ZMPSTE24 deficiency could benefit when treated with rapamycin and dimethylsulfoxidePharmacological modulation of arterial stiffness.Protein farnesylation and disease.Prenyltransferase Inhibitors: Treating Human Ailments from Cancer to Parasitic Infections.Pharmacological Inhibition of Protein Lipidation.Blocking farnesylation of the prelamin A variant in Hutchinson-Gilford progeria syndrome alters the distribution of A-type lamins.Enhanced SRSF5 Protein Expression Reinforces Lamin A mRNA Production in HeLa Cells and Fibroblasts of Progeria Patients.Progerin impairs chromosome maintenance by depleting CENP-F from metaphase kinetochores in Hutchinson-Gilford progeria fibroblasts.Targeting isoprenylcysteine methylation ameliorates disease in a mouse model of progeria.Intermittent treatment with farnesyltransferase inhibitor and sulforaphane improves cellular homeostasis in Hutchinson-Gilford progeria fibroblasts.Emerging candidate treatment strategies for Hutchinson-Gilford progeria syndrome.
P2860
Q21245032-931F5A8B-56F3-4D79-94B0-F4824AADACB1Q24564144-B5FA90A1-C6CD-458D-9A23-9BA1DD4BEB8BQ24594564-FB46705B-4B65-4D46-BA28-F2F7B7760D06Q26827624-D7DD2C8D-5A7A-4810-AA00-FD90C72529EBQ28068068-EDE53511-3880-4A5B-AA21-4FBBF606EEBAQ28251294-756285E2-9D05-45BB-98B2-927A46070923Q30428604-90C9574C-2CF9-4AFB-AC90-E9DC649009C5Q30540136-F998E178-4E40-46A8-B5B3-78963A6E1369Q33577875-874CB306-56D8-4055-A0F6-86140CB345E4Q33595869-6A357997-361F-4651-B73C-4D4F58D6CC51Q33755858-1AA91C25-E686-4340-B138-8AF09BAB526BQ33758494-A7B450A6-640C-42EA-9392-555EEBE32552Q33847777-06703093-535B-4A49-BD69-38C0F698AEE0Q33904465-CD4B2EED-1532-41ED-A1E2-ECA2409852BEQ34127512-7E51CC14-055D-4DC6-A582-741BF266A5DBQ34252203-719383BF-0D62-4253-AEBB-C7E92708F44FQ34470636-955E3F3F-8678-44F3-AB27-A6651BC81CCFQ35015891-EA0AA13C-BF52-4875-AB49-2DFB7E5F3D83Q35080536-E9203897-573E-4C40-95F1-D98EF151734EQ35956784-EEB74FD8-68D3-442C-BF12-78BA4B65BDB1Q36737860-D5C71358-FD7B-4E9E-900D-16C7326A161FQ36852109-D19200BD-8334-48B4-BEE6-1701032EE992Q37089986-703BF53B-0484-4624-AAB6-4FFAC3090FFCQ37323331-7EFC5748-B1A8-4843-82DC-E22F35C9257DQ37328057-0521AC6A-CC5D-4955-B342-0832747A113CQ37334608-4585FC5D-C152-4013-B0D1-2BB23C329A95Q37518612-7FF330DA-2A79-447F-851D-B83A0CF3605AQ37929160-34B9DCC5-D3EE-4C7A-8825-7D89AEB4C270Q37981563-7183E17F-E75A-40E5-AE13-815123A470B5Q38296605-81765ED3-5F2D-4B20-80AA-317020B35680Q38568187-22AAE50E-2068-4D3A-9F40-06EB678A0E05Q39297143-4BB4B40D-1BDC-487E-9D65-C086A12A3A89Q40209337-A296DE8F-A73E-43BD-959E-2AE970EE2D04Q41134538-3974A214-E3A2-4E06-826E-745CFAB8F7E3Q42278285-3B5E30EE-9405-42DD-9B3E-5FB21E5F6D19Q42371472-C5E5E97D-B413-40A1-96D7-98D3BE2FAADCQ47414799-6B08F097-8DBA-436E-BCE8-772B363EBAB6
P2860
Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson-Gilford progeria syndrome mutation.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Treatment with a farnesyltrans ...... rd progeria syndrome mutation.
@ast
Treatment with a farnesyltrans ...... rd progeria syndrome mutation.
@en
type
label
Treatment with a farnesyltrans ...... rd progeria syndrome mutation.
@ast
Treatment with a farnesyltrans ...... rd progeria syndrome mutation.
@en
prefLabel
Treatment with a farnesyltrans ...... rd progeria syndrome mutation.
@ast
Treatment with a farnesyltrans ...... rd progeria syndrome mutation.
@en
P2093
P2860
P1476
Treatment with a farnesyltrans ...... ord progeria syndrome mutation
@en
P2093
Loren G Fong
Shao H Yang
P2860
P356
10.1016/J.BBALIP.2007.11.003
P407
P577
2007-11-26T00:00:00Z